CSI Market
Sign In | Register

Krystal Biotech Inc (KRYS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KRYS Annual Cash Flow →
Cash flow data covering Krystal Biotech Inc–Jun 30 2025 offers a view into how Jun 30 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income110.70
Depreciation & amortization2.88
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed55.21
Increase (Decrease) in Inventories1.20
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Intangible Assets0.00
Share-based Compensation27.77
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Gains Losses On Sales Of Assets-
Accretion Expense Net-0.58
Operating Lease Right Of Use Asset Amortization Expense0.20
Increase Decrease In Lease Liability-0.23
Increase Decrease In Accrued Rebates12.69
Increase Decrease Accrued Legal Settlement And In Process Research And Development-
Increase Decrease Accrued Legal Settlement And In Process Research And Development-
Income taxes0.00
Realized Investment Gains (Losses), Total1.28
Increase (Decrease) in Accounts Receivable11.92
Increase (Decrease) in Accounts Payable4.08
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-0.87
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets3.19
Other Working Capital3.46
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-65.63
Discontinued operations0.00
Net Cash flow from Operating Activities155.17
Investing Activities
Capital Expenditures-10.71
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments203.60
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-418.06
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-225.17
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock21.66
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-17.07
Payments For Suit Liability-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents496.30
Capital Expenditures Incurred But Not Yet Paid1.22
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.59
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow144.46
Total Cash Flow-68.56
4 historic quarters locked

Sign in to unlock the full Krystal Biotech Inc cash flow history.

Sign In Create Free Account

About Krystal Biotech Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001711279-26-000057

Figures are derived from filed reports and may be restated. Historical data is subject to revision.